Skip to main content
TipRanks
Go Ultimate75% OFF

Krebs Biochemicals & Industries Ltd. (KREBSBIO) AI Stock Analysis

0 Followers
IN:KREBSBIO

Krebs Biochemicals & Industries Ltd.

(NSE:KREBSBIO)

Select Model
Rating:46Neutral
Price Target:INR 62.00â–²(5.30% Upside)
Action:reiterated
Date:10/27/26

The score is held down primarily by very weak financial performance (recurring losses, negative equity, and persistent negative free cash flow). Technicals provide a partial offset with the stock trading above major moving averages and moderately positive momentum. Valuation contributes little support given the negative P/E and no dividend yield data.

Positive Factors
Gross Margin RecoveryGross margin has returned to positive territory in 2025–2026, indicating better product-level economics than in earlier periods. If maintained, this could improve the company’s ability to cover operating costs and rebuild profitability, although it has not yet produced sustainable profits.
Negative Factors
Revenue ContractionRevenue has declined across several recent annual periods, including an approximately 13% contraction in 2026. Persistent top-line erosion can weaken operating leverage, reduce plant utilization, and make it harder for the company to spread fixed costs or restore sustainable profitability.

Krebs Biochemicals & Industries Ltd. (KREBSBIO) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%IN:KREBSBIO-14.65%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.28B
Dividend Yield
―
Average Volume (3M)
3,931
Price to Earnings (P/E)
-9.6
Beta (1Y)
1.00
Revenue Growth
-1.32%
EPS Growth
51.41%
Country
India
Employees
142
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Krebs Biochemicals & Industries Ltd. Business Overview & Revenue Model

Company Description

Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by developing...

How the Company Makes Money

KREBSBIO primarily makes money by manufacturing chemical products and selling them to customers, generating revenue from product sales (typically recognized upon dispatch/delivery under customer contracts). Its earnings are driven by (a) sales volume...

Krebs Biochemicals & Industries Ltd. Financial Statement Overview

Summary

Financial statements indicate severe strain: persistent EBIT/net losses with a very large latest-year net loss (about -71% net margin), contracting revenue in the latest year, negative shareholders’ equity across all years with high leverage/solvency risk, and ongoing cash burn with negative operating cash flow in most years and negative free cash flow in every year provided. A modest positive is gross margin turning positive again in 2025–2026, but it has not led to sustainable profitability.

Income Statement

14Very Negative

Balance Sheet

9Very Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue268.57M237.32M433.12M504.21M521.34M597.03M
Gross Profit124.25M65.30M377.56M-80.63M244.19M-57.64M
EBITDA3.35M-34.24M-143.21M-82.73M-151.62M-328.46M
Net Income-133.49M-169.33M-269.39M-197.28M-246.92M-445.27M
Balance Sheet
Total Assets1.59B1.63B1.69B1.78B1.75B1.90B
Cash, Cash Equivalents and Short-Term Investments1.26M1.29M3.38M1.37M858.00K1.01M
Total Debt2.27B2.25B2.12B2.39B1.83B1.88B
Total Liabilities3.29B3.26B3.15B2.97B2.74B2.65B
Stockholders Equity-1.71B-1.63B-1.46B-1.19B-994.62M-750.93M
Cash Flow
Free Cash Flow0-121.78M-114.54M-70.50M-355.84M-407.36M
Operating Cash Flow0-90.06M-78.91M23.65M-247.13M-172.16M
Investing Cash Flow0-36.36M-49.70M-78.17M-126.45M-229.00M
Financing Cash Flow0126.30M128.65M55.64M373.43M395.06M

Krebs Biochemicals & Industries Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price58.88

Price Trends

50DMA57.76Positive
100DMA57.13Positive
200DMA57.58Positive

Market Momentum

MACD0.01Negative
RSI52.52Neutral
STOCH65.87Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KREBSBIO, the sentiment is Positive. The current price of 58.88 is above the 20-day moving average (MA) of 57.78, above the 50-day MA of 57.76, and above the 200-day MA of 57.58, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 52.52 is Neutral, neither overbought nor oversold. The STOCH value of 65.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KREBSBIO.

Krebs Biochemicals & Industries Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:KREBSBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:PARIN:PAR73OutperformINR 1.46B11.27――9.40%34.12%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ALPAIN:ALPA54NeutralINR 1.17B33.08――0.46%-83.31%
IN:BALPHARMAIN:BALPHARMA53NeutralINR 1.43B18.27―1.33%18.79%-2.58%
IN:VIVIMEDLABIN:VIVIMEDLAB46NeutralINR 447.74M-0.24――-39.80%-452.04%
IN:KREBSBIOIN:KREBSBIO46NeutralINR 1.27B-9.58――-1.32%51.41%
IN:BIOFILCHEMIN:BIOFILCHEM41NeutralINR 506.12M105.85――9.31%-82.71%

* General Sector Average

Performance Comparison

0%100%200%300%400%IN:KREBSBIOIN:ALPAIN:BALPHARMAIN:BIOFILCHEMIN:PARIN:VIVIMEDLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:KREBSBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:KREBSBIOKrebs Biochemicals & Industries Ltd.58.88-10.11-14.65%
IN:ALPAAlpa Laboratories Limited55.61-24.36-30.46%
IN:BALPHARMABal Pharma Limited90.1011.3014.34%
IN:BIOFILCHEMBiofil Chemicals & Pharmaceuticals Ltd.31.10-8.68-21.82%
IN:PARPar Drugs and Chemicals Limited119.0024.8926.45%
IN:VIVIMEDLABVivimed Labs Limited5.400.5010.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026